Medivir AB

11:30 AM - 11:45 AM, Wednesday, June 5, 2019 ・ Theater 2
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share is listed on Nasdaq Stockholm's Small Cap list.
Ticker:
MVIR
Exchange:
Nasdaq Stockholm
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Sweden
Year Founded:
1988
Main Therapeutic Focus:
Lead Product in Development:
Remetinostat
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
EVP, Strategic Business Development
Medivir AB